Professor John Gribben graduated in medicine from the University of Glasgow in 1980. He was a doctoral fellow at University College London and in Medical Oncology at the Dana-Farber Cancer Institute, Harvard Medical School. He remained on the faculty for at Harvard Medical School 17 years before returning to the UK in 2005. He specializes in hematological cancers including lymphomas, leukemias and bone marrow transplantation and immunotherapy approaches including CAR-T cells. He holds the Hamilton Fairley Chair of Medical Oncology at Barts and the London School of Medicine, Queen Mary, University of London and his NHS post is as Honorary Consultant Medical Oncologist Barts and The London NHS Trust. He is the author of more than 500 articles and chapters in peer-reviewed publications and has a global reputation for his work in researching new drugs and forms of cancer treatment and the tole of immunotherapy in cancer. He has grant funding from The National Cancer Institute, Cancer Research UK, Wellcome Trust and the Medical Research Council for pioneering studies in leukaemia and lymphoma. He takes up his role as President of the European Hematology Association (EHA) for 2 years from June 2019 is currently serves on the EHA Executive Board. He is Chair of the international workshop for non-Hodgkin’s lymphoma (iwNHL) and co-chair of the international workshop for CAR T cells (iwCART). He was an Editor of Blood from 2007-2014. He is a on the Board of Trustees of the London Clinic.